Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/28/2854477/28889/en/Fortress-Biotech-Reports-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2024/03/12/2844540/28889/en/Fortress-Biotech-to-Participate-in-36th-Annual-ROTH-Conference.html
https://www.globenewswire.com//news-release/2024/03/04/2839612/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-4-1-Million-Grant-from-NINDS-to-Further-Development-of-AAV-ATP7A-Gene-Therapy-for-Menkes-Disease.html
https://www.globenewswire.com//news-release/2024/01/03/2803604/28889/en/Fortress-Biotech-Announces-Closing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2023/12/29/2802052/28889/en/Fortress-Biotech-Announces-Pricing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2023/12/06/2791767/28889/en/Cyprium-Therapeutics-a-Fortress-Biotech-Subsidiary-Company-Completes-Asset-Transfer-of-CUTX-101-Copper-Histidinate-Product-Candidate-for-Treatment-of-Menkes-Disease-to-Sentynl-Ther.html
https://www.globenewswire.com//news-release/2023/11/14/2780529/28889/en/Fortress-Biotech-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2023/11/14/2780484/28889/en/Fortress-Biotech-Announces-Closing-of-10-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/10/2778298/28889/en/Fortress-Biotech-Announces-Pricing-of-10-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/09/2777951/28889/en/Fortress-Biotech-Announces-Launch-of-Proposed-Public-Offering.html